TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.
Eisai, in partnership with BioArctic AB, has completed the rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for Alzheimer’s treatment. If approved, this would allow patients to administer the treatment at home, potentially reducing healthcare resource utilization and streamlining the Alzheimer’s treatment pathway.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company has a strategic research alliance with Eisai, and their primary product, Leqembi, is a monoclonal antibody targeting amyloid-beta, a hallmark of Alzheimer’s.
Average Trading Volume: 316,005
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.66B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.